Figure 2: Analysis of dopaminergic neurons: DAT expression in the striatum and TH immunoreactivity in the substantia nigra. (A) Representative total (upper) and non-specific (lower) binding of [125I]PE2I to the DAT in the non-lesioned intact (C-ST) and lesioned (I-ST) striatum of the control and PHA/PRE groups. (B) Quantification of the specific binding of [125I]PE2I in the C-ST and I-ST in both groups. (C) Representative immunostaining of TH (red) in the C-SN and I-SN of the control and PHA/PRE groups. (D) Measurement of TH positive cells in the C-SN and I-SN of both groups. Data are represented as the mean ± SD. n = 7/group. *P < 0.05, vs. contralateral area in the same group (Wilcoxon test); #P < 0.05 and ##P < 0.01 (Mann-Whitney U test). C-SN: Contralateral substantia nigra; C-ST: contralateral striatum; DAT: dopamine transporter; I-SN: ipsilateral substantia nigra; I-ST: Ipsilateral striatum; TH: tyrosine hydroxylase.